Merck KGaA posts strong 11.6% second-quarter sales growth
Shares of German drug and chemicals major Merck KGaA rose 3.3% to 85.39 euros this morning, after the company reported a strong et of second-quarter 2012 financial results, with 11.6% growth in total revenues to 2.85 billion euros ($3.51 billion) constituting organic growth of 5.1%, a 5.4% foreign exchange rates (Fx) benefit and a 0.5% increase from acquisition and divestments.
Operating results included 394 million euros in one-time impairments relating to the company’s “Fit for 2018” restructuring program. EBITDA pre (earnings before interest, taxes, depreciation, amortization and one-time items) rose 14% to 747 million euros, or 27.2% of sales. Net loss for the quarter was 60.5 million euros, versus 86.8 million euros in the like 2011 period.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze